Ultrasmall polyvinylpyrrolidone‐modified iridium nanoparticles with antioxidant and anti‐inflammatory activity for acute pancreatitis alleviation
Source abstract
Abstract
Abstract Acute pancreatitis (AP) is a common and serious acute inflammatory disease with high severity rate and mortality. Inflammation and oxidative stress play an extremely important role in the development of AP disease. Polyvinylpyrrolidone‐modified iridium nanoparticles (IrNP‐PVP) have multienzyme mimetic activity, and the aim of this article is to discuss the therapeutic alleviative effects of the ultrasmall nanozymes IrNP‐PVP on AP through their antioxidant and anti‐inflammatory effects. IrNP‐PVP were proved to inhibit inflammation and scavenge reactive oxygen species (ROS) at the cellular level. The synthetic IrNP‐PVP exhibit remarkable antioxidant and anti‐inflammatory activities in the prevention and treatment of AP mice by establishing murine AP model, which can reduce the oxidative stress and inflammatory response. The results of this article indicated that the ultrasmall nanozymes IrNP‐PVP effectively alleviate AP via scavenging ROS as well as suppressing inflammation both in vivo and in vitro, which might provide enormous promise for the AP management.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Pancreatitis Pathology and Treatment · COVID-19 Impact on Reproduction · COVID-19 Clinical Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Vascular Surgery The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang Province People's Republic of China
Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang Province People's Republic of China
Translational Medicine Laboratory The First Affiliated Hospital of Wenzhou Medical University Wenzhou People's Republic of China
Funding
Natural Science Foundation of Zhejiang Province
References (45)
Show source-provided references
1. 10.1016/S0140-6736(14)60649-810.1016/S0140-6736(14)60649-8 ↗
2. 10.1001/jama.2020.2031710.1001/jama.2020.20317 ↗
3. 10.1053/j.gastro.2018.12.04110.1053/j.gastro.2018.12.041 ↗
4. 10.1038/s41419-021-04227-010.1038/s41419-021-04227-0 ↗
5. 10.1038/s41419-021-03923-110.1038/s41419-021-03923-1 ↗
6. 10.1016/j.redox.2015.01.00210.1016/j.redox.2015.01.002 ↗
7. 10.1152/ajpcell.00283.200810.1152/ajpcell.00283.2008 ↗
8. Vitamin B 12 attenuates acute pancreatitis by suppressing oxidative stress and improving mitochondria dysfunction via CBS/SIRT1 pathway10.1155/2021/7936316 ↗
9. 10.3390/ijms2111400510.3390/ijms21114005 ↗
10. 10.1089/ars.2012.460910.1089/ars.2012.4609 ↗
11. 10.1016/j.molcel.2012.09.02510.1016/j.molcel.2012.09.025 ↗
12. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
13. 10.1002/path.149110.1002/path.1491 ↗
14. 10.1038/s41467-021-22278-x10.1038/s41467-021-22278-x ↗
15. 10.1002/adma.20210239110.1002/adma.202102391 ↗
16. 10.7150/thno.5201010.7150/thno.52010 ↗
17. 10.1016/j.cej.2022.13679210.1016/j.cej.2022.136792 ↗
18. 10.1016/j.heliyon.2019.e0222210.1016/j.heliyon.2019.e02222 ↗
19. The protective effect of nano‐curcumin in experimental model of acute pancreatitis: the involvement of TLR4/NF‐kB pathway
20. 10.1016/j.jep.2012.11.03210.1016/j.jep.2012.11.032 ↗
21. 10.1186/1477-3155-9-310.1186/1477-3155-9-3 ↗
22. 10.1016/j.biopha.2019.10862910.1016/j.biopha.2019.108629 ↗
23. 10.1002/ange.20191218210.1002/ange.201912182 ↗
24. 10.1016/j.biomaterials.2020.12057310.1016/j.biomaterials.2020.120573 ↗
25. 10.1016/j.ccr.2020.21365210.1016/j.ccr.2020.213652 ↗
26. 10.1016/j.nantod.2021.10107610.1016/j.nantod.2021.101076 ↗
27. 10.1002/adfm.20200156610.1002/adfm.202001566 ↗
28. 10.1007/s40097-022-00493-210.1007/s40097-022-00493-2 ↗
29. 10.1039/D0CC05427E10.1039/D0CC05427E ↗
30. 10.1007/s40820-022-00828-210.1007/s40820-022-00828-2 ↗
31. 10.1039/C7SC05476A10.1039/C7SC05476A ↗
32. 10.1126/sciadv.abb269510.1126/sciadv.abb2695 ↗
33. 10.1021/acsami.0c1757910.1021/acsami.0c17579 ↗
34. 10.1016/j.biomaterials.2022.12159710.1016/j.biomaterials.2022.121597 ↗
35. 10.1002/cmdc.20220046810.1002/cmdc.202200468 ↗
36. 10.1016/j.jcis.2010.11.03210.1016/j.jcis.2010.11.032 ↗
37. 10.1039/D2TB02798D10.1039/D2TB02798D ↗
38. Preparation of colloidal transition metals in polymers by reduction with alcohols or ethers
39. 10.1021/acsami.5b0127110.1021/acsami.5b01271 ↗
40. 10.1016/j.mtbio.2022.10024410.1016/j.mtbio.2022.100244 ↗
41. 10.1021/acsnano.2c0342210.1021/acsnano.2c03422 ↗
42. 10.1016/j.molimm.2021.12.01210.1016/j.molimm.2021.12.012 ↗
43. 10.1111/apha.1203710.1111/apha.12037 ↗
44. 10.1016/j.bbadis.2018.12.00410.1016/j.bbadis.2018.12.004 ↗
45. 10.1053/j.gastro.2017.10.01210.1053/j.gastro.2017.10.012 ↗